SCHEMBL22734124

SCHEMBL22734124

Cc1cnc(-c2cnc(NCCNc3ccccn3)nc2-c2ccc(Cl)cc2Cl)[nH]1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 6/20 0.73
CDK1 P06493 3/20 0.73
GSK3A P49840 3/20 0.73
CCNB2 O95067 2/20 0.73
CCNB1 P14635 2/20 0.73
CCNB3 Q8WWL7 2/20 0.73
RPS6KB1 P23443 1/20 0.73
CDK2 P24941 1/20 0.73
LIMK1 P53667 1/20 0.73
TAOK1 Q7L7X3 1/20 0.73
SLK Q9H2G2 1/20 0.73
CLK4 Q9HAZ1 1/20 0.73
CSNK1G1 Q9HCP0 1/20 0.73
ROS1 P08922 2/20 0.41
ADORA1 P30542 3/20 0.38
POLB P06746 1/20 0.36
MAPK14 Q16539 2/20 0.35
GAA P10253 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CRHR1 P34998 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23180940 0.87 GSK3B (0.57) GSK3BCDK1GSK3ACCNB2CCNB1
SCHEMBL19322385 0.87 GSK3B (0.70) GSK3BCDK1GSK3ACCNB2CCNB1
Laduviglusib SCHEMBL29359162 0.85 GSK3B (1.00) GSK3BCDK1GSK3ACCNB2CCNB1
Laduviglusib SCHEMBL29353709 0.85 GSK3B (1.00) GSK3BCDK1GSK3ACCNB2CCNB1
Laduviglusib SCHEMBL29351682 0.85 GSK3B (1.00) GSK3BCDK1GSK3ACCNB2CCNB1
Laduviglusib SCHEMBL151139 0.85 GSK3B (1.00) GSK3BCDK1GSK3ACCNB2CCNB1
Laduviglusib SCHEMBL29468026 0.84 GSK3B (0.98) GSK3BCDK1GSK3ACCNB2CCNB1
Laduviglusib SCHEMBL29361792 0.84 GSK3B (0.98) GSK3BCDK1GSK3ACCNB2CCNB1
Laduviglusib SCHEMBL30175104 0.84 GSK3B (0.98) GSK3BCDK1GSK3ACCNB2CCNB1
Laduviglusib SCHEMBL18301565 0.84 GSK3B (0.98) GSK3BCDK1GSK3ACCNB2CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3334820-B1 INDUCED EXTENDED PLURIPOTENT STEM CELLS, METHODS OF MAKING AND USING BEIHAO STEM CELL AND REGENERATIVE MEDICINE RES INSTITUTE CO LTD (CN) 2024-05-15 EP claimed
US-20240060051-A1 Method for Producing Naive Human IPS Cells From Somatic Cells KYOTO UNIVERSITY (JP) 2024-02-22 US disclosed
EP-4269571-A1 METHOD FOR PRODUCING NAIVE HUMAN IPS CELLS FROM SOMATIC CELLS Kyoto University (JP) 2023-11-01 EP disclosed
US-20200385683-A1 COMPOSITION AND METHOD FOR CULTURING ORGANOIDS ORGANOIDSCIENCES, LTD. (KR) 2020-12-10 US disclosed
CN-105658788-A Method for preparing dopaminergic neurons 武田药品工业株式会社 2016-06-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200385683-A1 COMPOSITION AND METHOD FOR CULTURING ORGANOIDS CNN2, FABP2, S100A4 GSK3B 1197/4885CDK1 389/4885GSK3A 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.